How the price of As­traZeneca's buy­out of Cin­Cor fell by $1.4B

Cin­Cor scored a $1.8 bil­lion buy­out deal with As­traZeneca ear­li­er this month, but ac­cord­ing to re­cent­ly re­leased doc­u­ments, it al­most walked away from the deal ta­ble with much more than that.

In Sep­tem­ber, As­traZeneca of­fered to buy Cin­Cor for $60 per share plus a con­tin­gent val­ue right of $6 per share, adding up to $3.2 bil­lion if all mile­stones had been achieved, ac­cord­ing to an SEC fil­ing pub­lished on Mon­day. How­ev­er, the Cin­Cor board and CEO Marc de Garidel want­ed to see more cash up­front.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER